
SLNCF
Healthcare · Biotechnology · $1.22B market cap
Latest report
Before the open
The next earnings date isn’t on the calendar yet.
Analyst consensus
Analyst estimates aren’t available for this symbol.
Beat estimates in 1 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Mar 5, 2026 | Before the open | -0.08 | -0.07 | +12.5% |
| May 8, 2025 | Before the open | -0.11 | -0.15 | -36.4% |
| Nov 14, 2024 | Before the open | -0.11 | -0.19 | -72.7% |
| Aug 15, 2024 | Before the open | -0.06 | -0.11 | -83.3% |
| Mar 13, 2024 | Before the open | -0.11 | -0.12 | -9.1% |
| Nov 14, 2023 | Before the open | -0.15 | -0.07 | +53.3% |
| Aug 16, 2023 | Before the open | -0.16 | -0.10 | +37.5% |
| Mar 15, 2023 | Before the open | 0.12 | -0.13 | -208.3% |
| Nov 10, 2022 | Before the open | -0.14 | -0.07 | +50.0% |
| Aug 11, 2022 | After the close | -0.12 | -0.13 | -8.3% |
| May 16, 2022 | Before the open | -0.14 | -0.09 | +35.7% |
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases. It…